Q1 2026 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2026-05-15 · accession 0001193125-26-225480
$163.1M
Reported value
10
Positions
2026-03-31
Period end
The Brief · Omega Fund Management, LLC · Q1 2026
AI · grounded in 13F
Omega Fund Management, LLC closed its entire position in Upstream Bio Inc. UPB, reducing its exposure by $36.0M. The fund also trimmed its holdings in Alumis Inc. ALMS by 63.1% and Kestra Med Technologies Ltd KMTS by 25.6%. Conversely, the manager accumulated more shares of Bicara Therapeutics Inc. BCAX, increasing the position by 8.5%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 055477103 | BCAX | Bicara Therapeutics Inc. | $47.6M | 29.2% | 2,392,150 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc. | $34.7M | 21.2% | 8,081,089 | Common | SOLE |
| 107924102 | BBOT | BridgeBio Oncology Therapeutics Inc. | $29.4M | 18.0% | 3,289,661 | Common | SOLE |
| G52441105 | KMTS | Kestra Med Technologies Ltd | $20.4M | 12.5% | 1,022,149 | Common | SOLE |
| 08659B102 | BBNX | Beta Bionics Inc. | $13.2M | 8.08% | 1,316,183 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $6.0M | 3.66% | 876,357 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $5.3M | 3.26% | 241,255 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $2.4M | 1.49% | 843,750 | Common | SOLE |
| 45175G207 | IMA | ImageneBio, Inc. | $2.3M | 1.40% | 455,361 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $1.9M | 1.17% | 248,672 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.